Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
SpineThera is developing a sustained-release injectable drug for back pain with the aims of improving safety and reducing the need for repeated epidural injections of corticosteroids.
Voyager Therapeutics is developing potentially life-changing gene therapies to treat advanced Parkinson’s disease and other serious neurological disorders with a significant unmet medical need.
The clinical impact of checkpoint inhibitors and their anticipated position as linchpins of future cancer immunotherapy regimens has driven a wave of dealmaking. In this feature, we chart the development progress and major deals for the leading checkpoint inhibitors.
A trend toward outsourcing early-stage R&D and thriving capital markets over the past few years have helped platform biotechs remain independent and able to ink creative deals with pharma companies.
Cambridge, UK – 20 September 2016 – F-star, a biopharmaceutical company developing novel bispecific antibodies with a focus on immuno-oncology, announces it is to present preclinical data on its lead bispecific programme FS118 at the upcoming American Association for Cancer Research (AACR) conferences.
With its unique Humabody technology platform, Crescendo Biologics is poised to become a significant player in the rapidly progressing immuno-oncology field.
With the key goal of improving the outcomes for people with cancer, university-launched OncoTherapy Science, Inc. is developing a pipeline of small-molecule drugs and a number of therapeutic peptide vaccines.
Norway’s ambitious oncology cluster is dedicated to accelerating the development of new cancer immuno-therapies through collaboration and new partnerships.
Exicure is pioneering the development of spherical nucleic acid technology as a promising avenue of therapeutic development to strengthen and prolong the body’s natural immune defenses against a wide range of cancers.
Merck has expanded its corporate venture capital arm to all of its business sectors under the newly named Merck Ventures and has doubled the total fund size to €300 million.
Plasticell is leveraging its innovative combinatorial screening technology for a broad range of cell and gene therapy applications, whereas spin-out Progenitor Therapeutics focuses on small-molecule regenerative drug discovery.
With its innovative fusion cancer vaccine that greatly enhances the target specificity of T cells, Tokyo-based CyTIX is poised to take advantage of the biopharma industry’s increasing interest in next-generation cancer vaccines.
BeyondSpring Pharmaceuticals’ plinabulin demonstrates a multifaceted approach that targets immune and vascular aspects of tumor growth, resulting in immune-enhancing effects.
Trianni has developed transgenic immunoglobulin mice capable of expressing the full human antibody repertoire, ideal for the discovery of new therapeutic antibody candidates.
Precision BioSciences is harnessing its next-generation genome editing platform, ARCUS, to develop a pipeline of cell-based immunotherapies for cancer and autoimmune disease, as well as gene therapies for rare genetic disorders. The company is looking for uniquely suited partners to aid in these efforts.
co.don AG currently markets its regenerative therapy methods in Germany, where uptake is increasing among orthopedic surgeons, trauma surgeons and neurosurgeons.
